Total-body Glucose Utilization in Obesity

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 25, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Obesity and Overweight
Interventions
BEHAVIORAL

Movies

Participants will watch eight short movie clips, and the changes different emotions evoked by the clips will be studied using H2\[15O\]O PET/CT.

BEHAVIORAL

Cold

Participants will be studied with H2\[15O\]O PET/CT while one of their legs will be exposed to cold to study the effects of cold stimulus on whole-body blood flow.

DRUG

Hyperinsulinemic euglycemic clamp

Participants will be administered intravenous fast acting insulin (NovoRapid, Novo Nordisk, 1 mU/m2 body surface area/min) together with 20 % glucose to maintain normal glucose values (5.0 mmol/L) to study the effects of insulin on whole body blood flow with H2\[15O\]O PET/CT, and to assess tissue insulin-stimulated glucose uptake with \[18F\]FDG PET/CT.

RADIATION

H2[15O]O PET/CT

H2\[15O\]O PET/CT, with a dose of 25-700 MB/bolus repeated 2-8 times per scan.

RADIATION

[18F]FDG PET/CT

Whole-body \[18F\]FDG PET/CT scan to study tissue glucose uptake, dose 100 MBq

DRUG

CEUS or Contrast enhanced Ultrasound

Contrast-enhanced ultrasound of left forearm muscles is performed during fasting and after 30-40 minutes of hyperinsulinemia

Trial Locations (1)

20521

RECRUITING

Turku PET Centre, Turku

All Listed Sponsors
lead

Turku University Hospital

OTHER_GOV